Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Lood, Christian ^a   Tydén, Helena ^a   Gullstrand, Birgitta ^b   Klint, Cecilia ^c   Wenglén, Christina ^c   Nielsen, Christoffer T ^d   Heegaard, Niels H H ^d   Jönsen, Andreas ^a   Kahn, Robin ^a   Bengtsson, Anders A ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Anamar AB   (Sweden)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON; KYNURENINE; SEROTONIN; TRYPTOPHAN; ANTINUCLEAR ANTIBODY;

ADULT; AGED; AMINO ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HORMONE SYNTHESIS; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SEROTONIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; ADOLESCENT; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; KIDNEY; METABOLISM; MIDDLE AGED; PATHOLOGY; SECRETION (PROCESS); SEVERITY OF ILLNESS INDEX; THROMBOCYTE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON TYPE I; KIDNEY; KYNURENINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PHENOTYPE; SEROTONIN; SEVERITY OF ILLNESS INDEX; TRYPTOPHAN;

EID: 84928886034     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125109     Document Type: Article

References (50)

1. Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010; 16(2):47-57. Epub 2010/02/09. doi: S1471-4914(10)00006-7 [pii] doi: 10.1016/j.molmed.2009.12.005 PMID: 20138006; PubMed Central PMCID: PMC2823952.
2. Rönnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci. 2011; 116(4):227-37. Epub 2011/11/10. doi: 10.3109/03009734.2011.624649 PMID: 22066971; PubMed Central PMCID: PMC3207297.
3. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus. 2008; 17(5):394-9. Epub 2008/05/21. doi: 17/5/394 [pii] doi: 10.1177/0961203308090020 PMID: 18490415.
4. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000; 9(9):664-71. Epub 2001/02/24. PMID: 11199920.
5. Lood C, Amisten S, Gullstrand B, Jönsen A, Allhorn M, Truedsson L, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood. 2010; 116(11):1951-7. Epub 2010/06/12. doi: blood-2010-03-274605 [pii] doi: 10.1182/blood-2010-03-274605 PMID: 20538795.
6. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther. 2003; 5(6):279-87. Epub 2003/12/19. doi: 10.1186/ar1015ar1015 [pii]. PMID: 14680503.
7. Furuzawa-Carballeda J, Lima G, Jakez-Ocampo J, Llorente L. Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study. Eur J Clin Invest. 2011; 41(10):1037-46. Epub 2011/03/04. doi: 10.1111/j.1365-2362.2011.02491.x PMID: 21366559.
8. Widner B, Sepp N, Kowald E, Ortner U, Wirleitner B, Fritsch P, et al. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology. 2000; 201(5):621-30. Epub 2000/06/02. doi: S0171-2985(00)80079-0 [pii] doi: 10.1016/S0171-2985(00)80079-0 PMID: 10834318.
9. Pertovaara M, Hasan T, Raitala A, Oja SS, Yli-Kerttula U, Korpela M, et al. Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol. 2007; 150(2):274-8. Epub 2007/08/23. doi: CEI3480 [pii] doi: 10.1111/j.1365-2249.2007.03480.x PMID: 17711489; PubMed Central PMCID: PMC2219350.
10. Campbell BM, Charych E, Lee AW, Moller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014; 8:12. Epub 2014/02/26. doi: 10.3389/fnins.2014.00012 PMID: 24567701; PubMed Central PMCID: PMC3915289.
11. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets. 2010; 9(6):791-800. Epub 2010/10/15. doi: BSP/CDTCNSND/E-Pub/00086 [pii]. PMID: 20942784.
12. Perez-De La Cruz V, Konigsberg M, Santamaria A. Kynurenine pathway and disease: an overview. CNS Neurol Disord Drug Targets. 2007; 6(6):398-410. Epub 2008/01/29. PMID: 18220779.
13. Schäfer A, Scheurlen M, Seufert J, Keicher C, Weissbrich B, Rieger P, et al. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. J Hepatol. 2010; 52(1):10-5. Epub 2009/11/10. doi: S0168-8278(09)00653-9 [pii] doi: 10.1016/j.jhep.2009.10.007 PMID: 19897271.
14. Fukami MH, Bauer JS, Stewart GJ, Salganicoff L. An improved method for the isolation of dense storage granules from human platelets. J Cell Biol. 1978; 77(2):389-99. Epub 1978/05/01. PMID: 649656; PubMed Central PMCID: PMC2110056.
15. Ni W, Watts SW. 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol. 2006; 33(7):575-83. Epub 2006/06/23. doi: CEP [pii] doi: 10.1111/j.1440-1681.2006.04410.x PMID: 16789923.
16. Li N, Wallen NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis. 1997; 8(8):517-23. Epub 1998/03/10. PMID: 9491270.
17. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009; 196(2):193-222. Epub 2009/02/18. doi: APS1964 [pii] doi: 10.1111/j.1748-1716.2009.01964.x PMID: 19220204.
18. Leon-Ponte M, Ahern GP, O'Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood. 2007; 109(8):3139-46. Epub 2006/12/13. doi: blood-2006-10-052787 [pii] doi: 10.1182/blood-2006-10-052787 PMID: 17158224; PubMed Central PMCID: PMC1852236.
19. Durk T, Panther E, Muller T, Sorichter S, Ferrari D, Pizzirani C, et al. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int Immunol. 2005; 17(5):599-606. Epub 2005/04/02. doi: dxh242 [pii] doi: 10.1093/intimm/dxh242 PMID: 15802305.
20. Soga F, Katoh N, Inoue T, Kishimoto S. Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol. 2007; 127(8):1947-55. Epub 2007/04/13. doi: 5700824 [pii] doi: 10.1038/sj.jid.5700824 PMID: 17429435.
21. Duerschmied D, Suidan GL, Demers M, Herr N, Carbo C, Brill A, et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood. 2013; 121(6):1008-15. Epub 2012/12/18. doi: blood-2012-06-437392 [pii] doi: 10.1182/blood-2012-06-437392 PMID: 23243271; PubMed Central PMCID: PMC3567335.
22. Cloutier N, Pare A, Farndale RW, Schumacher HR, Nigrovic PA, Lacroix S, et al. Platelets can enhance vascular permeability. Blood. 2012; 120(6):1334-43. Epub 2012/05/01. doi: blood-2012-02-413047 [pii] doi: 10.1182/blood-2012-02-413047 PMID: 22544703.
23. Shajib MS, Wang H, Kim JJ, Sunjic I, Ghia JE, Denou E, et al. Interleukin 13 and serotonin: linking the immune and endocrine systems in murine models of intestinal inflammation. PLoS One. 2013; 8(8): e72774. Epub 2013/09/10. doi: 10.1371/journal.pone.0072774 PONE-D-13-14207 [pii]. PMID: 24015275; PubMed Central PMCID: PMC3755966. doi: 10.1371/journal.pone.0072774
24. Kim JJ, Bridle BW, Ghia JE, Wang H, Syed SN, Manocha MM, et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol. 2013; 190(9):4795-804. Epub 2013/04/05. doi: jimmunol.1201887 [pii] doi: 10.4049/jimmunol.1201887 PMID: 23554310.
25. Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, et al. Regulation of the interferonalpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009; 60(8):2418-27. Epub 2009/08/01. 10.1002/art.24686. PMID: 19644885. doi: 10.1002/art.24686
26. Shajib MS, Khan WI. The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf). 2014. Epub 2014/12/03. 10.1111/apha.12430. PMID: 25439045.
27. Sarac H, Markeljevic J, Mokrovic G, Erdeljic V, Bozina N, Cicin-Sain L. Platelet serotonin in primary Sjogren's syndrome: level and relation with disease activity. J Neuroimmunol. 2012; 251(1-2):87-9. Epub 2012/07/24. doi: S0165-5728(12)00212-3 [pii] doi: 10.1016/j.jneuroim.2012.06.011 PMID: 22819441.
28. Krishnadas R, Cavanagh J. Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: a case report and review of the literature. J Med Case Rep. 2011; 5:112. Epub 2011/03/23. doi: 1752-1947-5-112 [pii] doi: 10.1186/1752-1947-5-112 PMID: 21418592; PubMed Central PMCID: PMC3072330.
29. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol. 2012; 8(9):534-42. Epub 2012/08/08. doi: nrrheum.2012.118 [pii] doi: 10.1038/nrrheum.2012.118 PMID: 22868927.
30. Kanai H, Tsuchida A, Yano S, Naruse T. Intraplatelet and urinary serotonin concentrations in systemic lupus erythematosus with reference to its clinical manifestations. J Med. 1989; 20(5-6):371-90. Epub 1989/01/01. PMID: 2534129.
31. Zeller J, Weissbarth E, Baruth B, Mielke H, Deicher H. Serotonin content of platelets in inflammatory rheumatic diseases. Correlation with clinical activity. Arthritis Rheum. 1983; 26(4):532-40. Epub 1983/04/01. PMID: 6838676.
32. Meyerhoff J, Dorsch CA. Decreased platelet serotonin levels in systemic lupus erythematosus. Arthritis Rheum. 1981; 24(12):1495-500. Epub 1981/12/01. PMID: 6459785.
33. Parbtani A, Frampton G, Yewdall V, Kasai N, Cameron JS. Platelet and plasma serotonin in glomerulonephritis. III: The nephritis of systemic lupus erythematosus. Clin Nephrol. 1980; 14(4):164-72. Epub 1980/10/01. PMID: 7428190.
34. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2):288-91. Epub 2002/02/13. PMID: 11838846.
35. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. Epub 1982/11/01. PMID: 7138600.
36. Bengtsson AA, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven RF, Axelsson B, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebocontrolled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(5):1579-88. Epub 2011/12/02. doi: 10.1002/art.33493 PMID: 22131101.
37. Leffler J, Martin M, Gullstrand B, Tydén H, Lood C, Truedsson L, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2012; 188(7):3522-31. Epub 2012/02/22. doi: jimmunol.1102404 [pii] doi: 10.4049/jimmunol.1102404 PMID: 22345666.
38. Lood C, Eriksson S, Gullstrand B, Jonsen A, Sturfelt G, Truedsson L, et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus - a possible link to venous thrombosis? Lupus. 2012; 21(13):1423-32. Epub 2012/08/11. doi: 0961203312457210 [pii] doi: 10.1177/0961203312457210 PMID: 22878256.
39. Lood C, Tyden H, Gullstrand B, Sturfelt G, Jonsen A, Truedsson L, et al. Platelet activation and antiphospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus. PLoS One. 2014; 9(6):e99386. Epub 2014/06/13. doi: 10.1371/journal.pone.0099386 PONE-D-14-02789 [pii]. PMID: 24922069; PubMed Central PMCID: PMC4055750. doi: 10.1371/journal.pone.0099386
40. Iversen LV, Ostergaard O, Nielsen CT, Jacobsen S, Heegaard NH. A heparin-based method for flow cytometric analysis of microparticles directly from platelet-poor plasma in calcium containing buffer. J Immunol Methods. 2013; 388(1-2):49-59. Epub 2012/12/19. doi: S0022-1759(12)00347-X [pii] doi: 10.1016/j.jim.2012.12.001 PMID: 23246793.
41. Ostergaard O, Nielsen CT, Iversen LV, Jacobsen S, Tanassi JT, Heegaard NH. Quantitative proteome profiling of normal human circulating microparticles. J Proteome Res. 2012; 11(4):2154-63. Epub 2012/02/15. doi: 10.1021/pr200901p PMID: 22329422.
42. Nielsen CT, Ostergaard O, Johnsen C, Jacobsen S, Heegaard NH. Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum. 2011; 63(10):3067-77. Epub 2011/06/28. doi: 10.1002/art.30499 PMID: 21702008.
43. Rönnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013; 25(2):248-53. Epub 2012/12/20. doi: 10.1097/BOR.0b013e32835c7e32 PMID: 23249830.
44. Shimizu T, Nomiyama S, Hirata F, Hayaishi O. Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem. 1978; 253(13):4700-6. Epub 1978/07/10. PMID: 26687.
45. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006; 54(6):1906-16. Epub 2006/06/01. doi: 10.1002/art.21890 PMID: 16736505.
46. Parbtani A, Frampton G, Cameron JS. Platelet and plasma serotonin concentrations in glomerulonephritis, II. Clin Nephrol. 1980; 14(3):112-23. Epub 1980/09/01. PMID: 7418277.
47. Ito T, Ikeda U, Shimpo M, Yamamoto K, Shimada K. Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation. 2000; 102(20):2522-7. Epub 2000/11/15. PMID: 11076827.
48. de las Casas-Engel M, Dominguez-Soto A, Sierra-Filardi E, Bragado R, Nieto C, Puig-Kroger A, et al. Serotonin skews human macrophage polarization through HTR2B and HTR7. J Immunol. 2013; 190(5):2301-10. Epub 2013/01/29. doi: jimmunol.1201133 [pii] doi: 10.4049/jimmunol.1201133 PMID: 23355731.
49. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD. Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther. 2008; 327(2):316-23. Epub 2008/08/19. doi: jpet.108.143461 [pii] doi: 10.1124/jpet.108.143461 PMID: 18708586.
50. Nau F Jr., Yu B, Martin D, Nichols CD. Serotonin 5-HT2A Receptor Activation Blocks TNF-alpha Mediated Inflammation In Vivo. PLoS One. 2013; 8(10):e75426. Epub 2013/10/08. doi: 10.1371/journal. pone.0075426 PONE-D-12-30869 [pii]. PMID: 24098382; PubMed Central PMCID: PMC3788795. doi: 10.1371/journal.pone.0075426